Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Subsequent Event (Details Textual) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
Note 13 - Subsequent Event (Details Textual) - USD ($)	Oct. 01, 2023	Sep. 06, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Hanmi Pharmaceuticals Co., Ltd. [Member]
Proceeds from Issuance of Common Stock		$ 3,000,000
Keystone [Member] \| First Back-End Commitment Shares [Member] \| Common Shares [Member]
Stock issued period description					The issuance of 7,547 First Back-End Commitment Shares was initiated in September and completed in October.
The 2022 Atm Offering [Member]
Shares issued					336,690		4,836
Proceeds from Issuance of Common Stock			$ 694,000	$ 0	$ 1,837,000	$ 0	$ 51,000
The 2022 Atm Offering [Member] \| Common Shares [Member]
Shares issued					337,000
Subsequent Event [Member] \| Keystone [Member] \| Common Shares [Member]
Shares issued	274,163
Subsequent Event [Member] \| Keystone [Member] \| First Back-End Commitment Shares [Member] \| Common Shares [Member]
Shares issued	7,547
Subsequent Event [Member] \| Cash Received in October [Member] \| Keystone [Member] \| Common Shares [Member]
Shares issued	248,759
Proceeds from Issuance of Common Stock	$ 600,000
Subsequent Event [Member] \| Cash Received in September [Member] \| Keystone [Member] \| Common Shares [Member]
Shares issued	17,857
Proceeds from Issuance of Common Stock	$ 50,000